APR 23, 2018 08:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
UFH monitoring focusing on use of anti-Xa for critically ill and general patient management
Presented at the Stago EdVantage Virtual University Virtual Event
3 1 91

  • Professor of Anesthesiology, Professor of Surgery (Cardiothoracic), CoDirector, Cardiothoracic ICU, Duke University Hospital
      Jerrold Levy is Professor of Anesthesiology and Surgery (Cardiothoracic), and CoDirector of the Cardiothoracic Surgical Intensive Care Unit at Duke University Medical Center in Durham, NC. He obtained his medical degree from the University of Miami, FL, where he was an intern in internal medicine, and undertook his residency in the Department of Anesthesiology of the Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, where he was also Chief Resident, and completed fellowships in both Respiratory ICU and Cardiac Anesthesiology. He previously was Professor, Deputy Chair for Research, and Chief of Cardiothoracic Anesthesiology at Emory University. His clinical and research interests include therapeutic strategies to prevent and treat bleeding; anticoagulation and its reversal, clinical applications of recombinant and purified protein concentrates, therapeutic approaches to shock/ventricular dysfunction, and anaphylaxis. Some of his current appointments include Executive Editor of Anesthesiology, Co-chair of the Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis for the International Society of Thrombosis and Hemostasis, Cardiac Surgical Council of the American Heart Association, and consultant to the FDA's Blood Products Advisory Committee. He has authored over 400 publications, including original research articles, reviews, books, and book chapters.


    Despite the development of new anticoagulants, unfractionated heparin (UFH) continues to be a primary choice for intravenous anticoagulant therapy because of its titratability, short half-life, ability to use in patients with renal failure, and acute reversibility. UFH continues to be the mainstay of parenteral anticoagulation especially in critically ill patients and to maintain anticoagulation during mechanical cardiopulmonary support.  As with all intravenous anticoagulants, monitoring is required for its use. In critically ill patients, UFH can be monitored by multiple tests that include the activated partial thromboplastin time (aPTT), heparin activity measured by antifactor Xa (anti-Xa), or activated clotting time (ACT). Although the aPTT and the ACT are frequently used for monitoring, there are multiple limitations. Anti-Xa heparin monitoring represents an important alternative, and I routinely used anti-Xa monitoring as our standard of measurement in my previous institution. However, aPTT is the standard for monitoring in my current institution.  Despite this, I frequently use anti-Xa monitoring as an important guide to therapy especially in critically ill, complex patients especially during ECMO and mechanical cardiopulmonary support. Anti-Xa monitoring is a more direct measure of UFH activity than the aPTT, demonstrates less variability and is most helpful when conflicting values occur during aPTT monitoring.  In this presentation, I will review UFH monitoring focusing on the use of the anti-Xa for critically ill and general patient management.

    Learning Objectives

    • Summarize different methods for heparin monitoring in the ICU and hospital
    • Describe limitations and benefits of different testing focusing on anti-Xa monitoring
    • Discuss the role of anti-Xa monitoring and clinical applications in critically ill patients

    Show Resources
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds